1. Sato, S, Hirakata, M, Kuwana, M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52:1571-1576.
Google Scholar | Crossref | Medline2. Romero-Bueno, F, Diaz Del Campo, P, Trallero-Araguás, E, et al. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum. 2020;50:776-790.
Google Scholar | Crossref | Medline3. Abe, Y, Kusaoi, M, Tada, K, Yamaji, K, Tamura, N. Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy. Rheumatology (Oxford). 2020;59:767-771.
Google Scholar | Crossref | Medline4. Reeves, HM, Winters, JL. The mechanisms of action of plasma exchange. Br J Haematol. 2014;164:342-351.
Google Scholar | Crossref | Medline | ISI5. Yoshida, T, Minakuchi, H, Takahashi, R, Morita, S, Oya, M. Safety and efficacy of plasma exchange via direct femoral vein puncture in autoimmune blistering diseases. J Clin Apher. 2020;35:172-177.
Google Scholar | Crossref | Medline6. Endo, Y, Koga, T, Suzuki, T, et al. Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: a case report. Medicine (Baltimore). 2018;97:e0436.
Google Scholar | Crossref7. Silveira, MG, Selva-O’Callaghan, A, Ramos-Terrades, N, Arredondo-Agudelo, KV, Labrador-Horrillo, M, Bravo-Masgoret, C. Anti-MDA5 dermatomyositis and progressive interstitial pneumonia. QJM. 2016;109:49-50.
Google Scholar | Crossref | Medline8. Sasaki, N, Ishii, A, Kurabayashi, T, et al. Early initiation of plasma exchange therapy for a patient with anti-MDA5 autoantibody-positive dermatomyositis developing rapidly progressive interstitial lung disease. Mod Rheumatol Case Rep. 2021;5:87-94.
Google Scholar | Crossref | Medline9. Yamagata, A, Arita, M, Tanaka, A, et al. Therapeutic plasma exchange for clinically amyopathic dermatomyositis (CADM) associated with rapidly progressive interstitial pneumonia. J Clin Apher. 2020;35:435-443.
Google Scholar | Crossref | Medline10. Shirakashi, M, Nakashima, R, Tsuji, H, et al. Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment. Rheumatology (Oxford). 2020;59:3284-3292.
Google Scholar | Crossref | Medline11. Saito, T, Mizobuchi, M, Miwa, Y, et al. Anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease treated with therapeutic plasma exchange: a case series. J Clin Apher. 2021;36:196-205.
Google Scholar | Crossref | Medline12. Lundberg, IE, Tjärnlund, A, Bottai, M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76:1955-1964.
Google Scholar | Crossref | Medline13. Kagawa, H, Tsujino, K, Yamamoto, Y, et al. Acute lung injury after plasma exchange in a patient with anti-MDA5 antibody-positive, rapidly progressive, interstitial lung disease: a case report. Respir Med Case Rep. 2020;29:101016.
Google Scholar | Crossref | Medline14. Gono, T, Kawaguchi, Y, Satoh, T, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010;49:1713-1719.
Google Scholar | Crossref | Medline | ISI15. Fujiki, Y, Kotani, T, Isoda, K, et al. Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients. Mod Rheumatol. 2018;28:133-140.
Google Scholar | Crossref | Medline16. Sato, S, Masui, K, Nishina, N, et al. Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients. Rheumatology (Oxford). 2018;57:1212-1221.
Google Scholar | Crossref | Medline17. Gono, T, Masui, K, Nishina, N, et al. Risk prediction modeling based on a combination of initial serum biomarker levels in polymyositis/dermatomyositis-associated interstitial lung disease. Arthritis Rheumatol. 2021;73:677-686.
Google Scholar | Crossref | Medline18. Oddis, CV, Reed, AM, Aggarwal, R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65:314-324.
Google Scholar | Crossref | Medline